Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 13/20 | 0.38 |
| ▸ | HRH1 | P35367 | 13/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28898592 | 0.80 | CYP2C19 (0.43) | CYP2C19HRH2HRH1TSHRUSP2 | |
| SCHEMBL20857025 | 0.77 | CYP2C19 (0.48) | CYP2C19HRH2HRH1TSHRUSP2 | |
| SCHEMBL20857024 | 0.76 | CYP2C19 (0.55) | CYP2C19HRH2HRH1TSHRUSP2 | |
| SCHEMBL20865636 | 0.75 | CYP2C19 (0.51) | CYP2C19HRH2HRH1TSHRUSP2 | |
| SCHEMBL26209114 | 0.73 | CYP2C19 (0.49) | CYP2C19HRH2HRH1TSHRUSP2 | |
| SCHEMBL21078258 | 0.71 | HTR1A (0.46) | CYP2C19HRH1TSHRDRD3 | |
| SCHEMBL20857027 | 0.70 | CYP2C19 (0.61) | CYP2C19TSHRUSP2LMNA | |
| SCHEMBL7503597 | 0.68 | SLC6A3 (0.44) | CYP2C19HRH1TSHRDRD3 | |
| SCHEMBL20865637 | 0.68 | CYP2C19 (0.48) | CYP2C19HRH2HRH1TSHRUSP2 | |
| SCHEMBL22213099 | 0.67 | LPAR3 (0.47) | HRH2HRH1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417281-A | Anti-inflammatory, anti-cancer and anti-angiogenic compounds, pharmaceutical compositions and methods of making and using the same | 麦迪康制药公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-111655666-B | Anti-inflammatory, anti-cancer and anti-angiogenic compounds, pharmaceutical compositions and methods of making and using the same | 麦迪康制药公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | CYP2C19 666/4885HRH2 3489/4885HRH1 4265/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | CYP2C19 666/4885HRH2 3489/4885HRH1 4265/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | CYP2C19 666/4885HRH2 3489/4885HRH1 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.